Navigation Links
Declining breast cancer incidence in Canada with declining HRT usage
Date:9/23/2010

Breast cancer incidence declined among postmenopausal women in Canada as their use of hormone therapy declined, according to a study published online September 23 in The Journal of the National Cancer Institute.

The Women's Health Initiative (WHI) trial of more than 16,000 postmenopausal women in the United States reported in 2002 that the risks of combined estrogen and progestin hormone replacement therapy outweighed the benefits. As a result, prescriptions for hormone therapy fell dramatically in several countries around the world and so did the incidence of breast cancer.

To determine whether a similar decline of hormone therapy use and breast cancer incidence occurred in Canada, Prithwish De, Ph.D., of the Canadian Cancer Society, and colleagues, analyzed data from various Canadian registries and from a national health survey for women aged 50-69 years. Specifically, the researchers looked at information on prescriptions for hormone replacement therapy, breast cancer incidence, mammography rates, and self-reported use of hormone replacement therapy.

The researchers found that "the nearly 10% drop in invasive breast cancer rates coincided with the decline in use of hormone replacement therapy reported among Canadian women aged 50-69 years." The steepest decline in use occurred between 2002 and 2004, when use dropped from 12.7% to 4.9%. In that same period, breast cancer incidence dropped 9.6% but mammography rates remained stable.

The researchers write that the decline in breast cancer incidence "is likely explained by the concurrent decline in the use of hormone replacement therapy among Canadian women." They also say the drop in hormone therapy use may be partly explained by the media's coverage of results of both the WHI and the Million Women Study in the U.K., both of which showed that breast cancer risk was elevated with the use of combined hormone therapy. In Canada, cancer rates began to increase again in 2005 among women aged 50-69 years, which might be further evidence of a link between hormone therapy and breast cancer, according to the authors.

"Such a rebound might be expected if occult hormone-sensitive tumors were merely slowed by the withdrawal of hormone replacement therapy rather than prevented by it. If so, hormone replacement therapy may be thought to act as a promoter, rather than a cause of breast cancer," they write.

The study's limitations include the fact that data on hormone replacement therapy use was self-reportedand therefore subject to recall biasand that data on frequency or duration of use were not collected. Also, data on receptor status of breast tumors were not collected.

In conclusion, the authors write that "further long-term surveillance studies of trends between hormone replacement therapy and breast cancer incidence can help reconcile the potential population-level associations of these two factors."


'/>"/>

Contact: Kristine Crane
Kristine.Crane@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Youth exposure to alcohol ads in magazines declining
2. Preterm Birth Rates Declining, U.S. Report Shows
3. Declining social security benefits keep older men in workforce
4. Rates of Premature Adult Death Declining Worldwide
5. Survey Finds Access to Mammograms Declining for Women Under Age 50
6. Sexual Problems May Arise After Breast Cancer
7. Mammograms Cut Breast Cancer Death Rates, But Only Modestly: Study
8. 70 percent of women likely to experience sexual problems after breast cancer
9. Physical limitations of breast cancer survivors
10. Studies identify complications in women undergoing mastectomy and immediate breast reconstruction
11. Breast Reconstruction After Mastectomy: Now or Later?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... The number of chronically ... aging – meaning that there is an urgent need for highly skilled care managers ... solution, delivering a multi-pronged approach to train and retain care managers, and enhance their ...
(Date:4/28/2016)... ... ... offering a special deal on its webstore. , Buy 1 product and get ANYTHING (including ... with lesser value. In addition, a free bonus of 3 top serums in a ... many women (men, too) love our products and get good results. We want to introduce ...
(Date:4/28/2016)... Oaks, CA (PRWEB) , ... April 28, 2016 , ... ... is currently number one in Central America and is looking to grow their market ... marketing for such an exceptional brand as La Sirena Foods and indirectly ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... a new CDISC standard, Clinical Trial Registry (CTR) XML. Clinical trial registries ... will make it possible to build applications that generate submissions for multiple, ...
(Date:4/28/2016)... West Palm Beach, FL (PRWEB) , ... April 28, 2016 , ... ... time for the spring season. Smart pots are frequently used by professional organic farmers ... time for growers to order their supply of fabric pots. Our goal is to ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... 2016  ValGenesis, Inc., the market leader ... today announced that a prominent world provider ... chronic kidney failure has selected ValGenesis Validation ... validation process. The global medical device manufacturer ... manage their validation processes electronically. Upon completion ...
(Date:4/27/2016)... BASEL , Schweiz, April 27, 2016 ... des Sachs CEO Forums in Zürich ... Phase-II-Studie ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung ... (CI) eingesetzt wurde, bekannt. Für die umfassende ... Deutschland und Frankreich angeworben. STR001 wird während ...
Breaking Medicine Technology: